ILMN Stock Analysis & Forecast (2026)

Illumina, Inc. Healthcare Diagnostics & Research
$131.81
Current Price
80%
Strong Buy
View Plans
Data refreshed: April 22, 2026

Key Financial Metrics

Market Cap
$20.15B
P/E Ratio (TTM)
24.2x
P/E Forward
22.6x
Revenue Growth
5.0%
Gross Margin
68.2%
Net Margin
19.6%
Return on Equity
33.4%
Debt/Equity
0.94

AI Analysis Summary

Illumina, Inc. (ILMN) is a Healthcare company in the Diagnostics & Research industry with a 80% Strong Buy Score. Key strengths include Gross Margin (68.2%), Net Margin (19.6%), Return on Equity (33.4%). Our AI evaluates 8 fundamental categories including revenue growth, margin quality, balance sheet strength, cash flow generation, return on capital, and valuation metrics.

Revenue Growth: Moderate Gross Margin: Excellent Net Margin: Good Return on Equity: Excellent Debt/Equity: Elevated

This analysis is generated by StrongBuyAnalytics AI using publicly available financial data from SEC filings, earnings reports, and market feeds. It is not personalized investment advice. See our methodology and disclaimer.

ILMN Fundamental Analysis Report
PDF Report Preview
80%
Strong Buy Score
  • 8 Fundamental Categories Analyzed
  • Revenue & Growth Trends
  • Margin & Profitability Analysis
  • Balance Sheet Strength
  • Cash Flow Quality
  • Valuation Assessment
  • AI-Powered Investment Insights
Get Your Free ILMN Report

How It Works: AI Stock Analysis in 60 Seconds

See how our AI analyzes ILMN fundamentals to generate buy/sell signals and Strong Buy Scores.

Why ILMN Has a 80% Score

Our AI evaluates Illumina, Inc.'s fundamentals across multiple dimensions. Here is what is driving the current Strong Buy rating:

Recent Catalysts for ILMN

Key developments and data points that may impact Illumina, Inc.'s trajectory:

Earnings grew 86.4% — accelerating profitability could drive re-rating.
Wall Street consensus target is $136.11 (+3.3% from current price), based on 18 analyst estimates.
Analyst consensus recommendation: Buy.
Institutional ownership at 108.0% — strong smart-money backing.

ILMN vs. Peers

How Illumina, Inc. stacks up against comparable Healthcare companies on key metrics:

Ticker Price Market Cap P/E Rev Growth Net Margin ROE
ILMN $131.81 $20.15B 24.2x 5.0% 19.6% 33.4%
JNJ $227.02 $547.10B 20.6x 9.9% 21.8%
UNH $353.72 $321.06B 26.8x 12.3% 2.7% 12.5%
PFE $27.27 $155.15B 20.1x -1.2% 12.4% 8.9%
MRK $112.73 $278.71B 15.5x 5.0% 28.1% 36.9%

Main Risks for ILMN Investors

Every investment carries risk. Here are the specific risk factors our analysis identified for Illumina, Inc.:

High beta of 1.49 means the stock is 49% more volatile than the market — expect larger drawdowns in corrections.
Short interest is elevated with a 4.8-day cover ratio, indicating bearish bets against the stock.

Generate the full PDF report for a detailed risk-reward framework and bear-case scenarios.

ILMN Balance Sheet & Cash Flow

A snapshot of Illumina, Inc.'s financial health based on the most recent filings:

Total Cash
$1.63B
Total Debt
$2.55B
Current Ratio
2.08
FCF Yield
3.9%
EBITDA
$1.14B
Operating Margin
19.7%

Data sourced from the latest SEC filings. Generate the full PDF report for detailed balance sheet and cash flow commentary.

ILMN Valuation Snapshot

Trailing P/E
24.2x
Fairly valued
Forward P/E
22.6x
Earnings growth expected
Price / Book
7.4x
Premium
PEG Ratio
2.42
Expensive vs growth
Analyst Target (Mean)
$136.11
Range: $80 – $170
52-Week Price Range — ILMN is trading at 71% of its range
$73.86 (52W Low) $155.53 (52W High)

Is ILMN a Buy Right Now?

Based on our AI-powered fundamental analysis, ILMN has a Strong Buy Score of 80%, earning a "Strong Buy" rating. This score synthesizes 8 key financial metrics to provide an objective investment signal.

Strong Buy Signal

Illumina, Inc. demonstrates robust fundamentals across multiple categories. Key strengths include Gross Margin (68.2%) and Net Margin (19.6%). The stock shows characteristics typically associated with outperformers.

ILMN AI Buy & Sell Signals Explained

Our AI analyzes Illumina, Inc.'s financial statements to generate buy/sell signals based on quantitative metrics, not market sentiment or news headlines. Here's what drives the 80% score:

  • Revenue Growth: 5.0% year-over-year (positive)
  • Gross Margin: 68.2% (strong pricing power)
  • Net Margin: 19.6% (highly profitable)
  • Return on Equity: 33.4% (excellent capital efficiency)

Generate the full PDF report for complete category-by-category scoring and AI-powered investment recommendations.

Key Support / Demand Zones

Technical traders can view real-time demand and supply zones for ILMN on our Demand Zones page. These zones identify key price levels where institutional buying or selling has historically occurred.

With ILMN currently trading at $131.81, our system monitors proximity to these critical levels and can alert you when the stock approaches support or resistance zones.

Subscribe to demand zone alerts to receive real-time notifications when ILMN reaches key technical levels.

Earnings & Revenue Outlook

Illumina, Inc. operates in the Healthcare sector, specifically in Diagnostics & Research. Understanding earnings trends is crucial for forecasting ILMN's trajectory.

Current revenue growth of 5.0% slightly beats the average company.

Visit our Earnings Calendar to track upcoming ILMN earnings dates and historical beat/miss patterns. Sign up for earnings alerts to get notified before announcements.

ILMN Stock Forecast (Next 3–12 Months)

Our AI projects ILMN's trajectory based on current fundamentals and historical patterns. With a 80% Strong Buy Score, here's what the data suggests:

Bullish Outlook: Illumina, Inc. shows strong fundamental momentum. Net margins of 19.6% indicate pricing power and operational efficiency. Stocks with similar profiles have historically outperformed over 12-month periods.

For a complete 12-month price forecast with specific bull/bear scenarios, generate the full PDF report.

Valuation Metrics (P/E, Growth, Margins)

Understanding valuation is critical for determining if ILMN is fairly priced. Here's the current snapshot:

  • Market Capitalization: $20.15B
  • P/E Ratio (TTM): 24.2x (fairly valued)
  • Forward P/E: 22.6x (based on analyst estimates)
  • Debt/Equity: 0.94 (moderate leverage)

Our AI weighs these metrics against growth rates and margin quality to determine if ILMN offers compelling risk-adjusted returns at current prices.

Bull Case for ILMN

Here's why investors are bullish on Illumina, Inc.:

  • Gross Margin (68.2%)
  • Net Margin (19.6%)
  • Return on Equity (33.4%)

With a 80% Strong Buy Score, the bull case is well-supported by current fundamentals. The stock exhibits characteristics of quality compounders that tend to outperform long-term.

Bear Case & Risks for ILMN

Every investment carries risk. Here are potential concerns for ILMN investors:

  • Competitive pressures in Healthcare
  • Macroeconomic sensitivity and interest rate exposure
  • Execution risk on growth initiatives
  • Valuation compression if growth slows

The full PDF report includes a detailed bear case analysis with specific risk ratings for each category.

Summary / 12-Month Outlook

ILMN Summary: Illumina, Inc. earns a 80% Strong Buy Score based on AI analysis of fundamental data. Trading at $131.81 with a $20.15B market cap, the stock shows strong fundamentals supporting a bullish 12-month outlook.

Bull Case: Gross Margin (68.2%), Net Margin (19.6%)

For the complete analysis with specific price considerations, growth projections, and AI-powered buy/hold/sell recommendations, generate your free ILMN PDF report.

Learn More About Stock Analysis

Deepen your understanding of the concepts used in this ILMN analysis:

Fundamental Analysis Guide

Learn how to evaluate stocks using financial statements and key metrics.

Understanding P/E Ratio

What P/E ratio tells you about a stock's valuation and growth expectations.

Return on Equity (ROE)

Why ROE matters for stock selection and how to interpret it.

Stock Valuation Methods

Compare DCF, P/E, and other approaches to value stocks like ILMN.

What Are Demand Zones?

Find key support and resistance levels for ILMN and other stocks.

How to Read Earnings Reports

Understand earnings per share, revenue surprises, and guidance.

Related Tools for ILMN

Demand Zone Analyzer ILMN Live Chart ILMN SEC Filing News Earnings Calendar Institutional Ownership Sector Scanner Average Down Calculator

ILMN SEC Filing News

Latest SEC filings for ILMN explained in plain English — insider buys/sells (Form 4), proposed sales (Form 144), material events (8-K), and quarterly & annual reports.

Loading recent SEC filings…
View all ILMN SEC Filing News →

Frequently Asked Questions about ILMN

Is ILMN a good buy right now?
ILMN currently has a Strong Buy Score of 80% (Strong Buy). Based on AI analysis of fundamentals, ILMN shows strong buy signals with solid revenue growth, margins, and return metrics. Generate a free PDF report for specific buy/hold/sell recommendations.
What is the ILMN stock forecast for 2026?
Our AI forecasts ILMN based on current fundamentals: revenue growth of 5.0%, net margin of 19.6%, and P/E of 24.2x. The 80% Strong Buy Score reflects our outlook combining growth trajectory, margin quality, and valuation. See the full 12-month projection in your PDF report.
What are key support and resistance levels for ILMN?
View real-time ILMN demand zones (support) and supply zones (resistance) on our Demand Zones page. With ILMN currently at $131.81, you can see how close the stock is to key technical levels. Subscribe to get alerts when ILMN approaches these zones.
How do ILMN fundamentals compare to peers?
Illumina, Inc. operates in the Healthcare sector. Key metrics for peer comparison: Gross margin 68.2%, ROE 33.4%, Debt/Equity 0.94. The 80% Strong Buy Score factors in how these metrics stack up against industry averages. Data is refreshed daily.
Is the ILMN analysis PDF report free?
Yes! Your first ILMN fundamental analysis report is completely free with no credit card required. The PDF includes the full Strong Buy Score breakdown, all 8 fundamental categories analyzed, AI-powered insights, and specific investment recommendations. Additional reports are available through our subscription plans starting at $24/month.
What is Illumina, Inc.'s market cap and P/E ratio?
Illumina, Inc. (ILMN) has a market cap of $20.15B and a trailing P/E ratio of 24.2x (forward P/E: 22.6x). These valuation metrics are key factors in our Strong Buy Score calculation. See all metrics in the PDF report for comprehensive valuation analysis.

This ILMN analysis is for educational and informational purposes only and does not constitute financial advice. All data is sourced from public filings and market feeds. Past performance does not guarantee future results. Read our full disclaimer.